Conference Reports for NaTaP

EASL - The International Liver Congress 2015 50th annual Meeting of the European association for the Study of the Liver Vienna, austria  april 22-26 Back

Malachite-I Phase 3b Trial of Ombitasvir/Paritaprevir/r and Dasabuvir ± Ribavirin or Telaprevir + Peginterferon/Ribavirin in Treatment-Naïve Adults With Hcv Genotype 1       Reported by Jules Levin EASL 2015 April 22-26 Vienna Austria   Brian Conway1, Ewa Janczewska2, Yan Luo3, Manuela Curescu4, Susan Greenbloom5, Adrian Streinu-Cercel6, Florin Alexandru Caruntu7, Wayne Ghesquiere8, Brygida Knysz9, Wodzimierz Mazur10, Adriana Motoc11, Alejandro Soza12, Victoria Arama6, Olav Dalgard13, Danielle Sullivan3, Xuan Liu3, Mudra Kapoor3, Yan Liu3, Andrew Campbell3, Thomas Podsadecki3 1Vancouver Infectious Diseases Centre, Vancouver, British Colombia, Canada; 2ID Clinic, Mysowice, Poland; 3AbbVie Inc., North Chicago, Illinois, United States; 4Clinic of Infectious Diseases, University of Medicine and Pharmacy Timisoara, Timisoara, Romania; 5Toronto Digestive Disease Associates, Toronto, Ontario, Canada; 6Carol Davila University of Medicine and Pharmacy, National Institute for Infectious Diseases, Bucharest, Romania; 7National Institute for Infectious Diseases "Prof. Dr. Matei Bals", Bucharest, Romania; 8Island Health Authority, Section of Infectious Diseases, Victoria, British Colombia, Canada; 9Wroclaw Medical University, Wroclaw, Poland; 10Clinical Department of Infectious Disease, Medical University of Silesia, Katowice, Poland; 11Hospital of Infectious Diseases Dr. Victor Babes, Bucharest, Romania; 12Department of Gastroenterology, Pontificia Universidad Católica de Chile, Santiago, Chile; 13Akershus University Hospital, Lorenskog, Norway